Related references
Note: Only part of the references are listed.Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population
Mohammad Safiqul Islam et al.
CLINICA CHIMICA ACTA (2013)
Association between CYP2A6 genetic polymorphisms and lung cancer: A meta-analysis of case-control studies
Tao Liu et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Association between Cancer Risk and Drug-metabolizing Enzyme Gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) Polymorphisms in Cases of Lung Cancer in Japan
Yuichiro Tamaki et al.
DRUG METABOLISM AND PHARMACOKINETICS (2011)
Relationship Between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 Variation and Smoking Behaviors and Lung Cancer Risk
Catherine A. Wassenaar et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais
Sompop Peamkrasatam et al.
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk
T Kamataki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians
GM Vasconcelos et al.
PHARMACOGENOMICS JOURNAL (2005)
Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort
N Gambier et al.
PHARMACOGENOMICS JOURNAL (2005)
Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese
N Ariyoshi et al.
PHARMACOGENETICS (2004)
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians
KA Schoedel et al.
PHARMACOGENETICS (2004)
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers
M Fujieda et al.
CARCINOGENESIS (2004)
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism
R Yoshida et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles
C Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19
SMG Hoffman et al.
PHARMACOGENETICS (2001)
Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population
MA Loriot et al.
PHARMACOGENETICS (2001)
Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
M Nakajima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase
H Kushida et al.
CARCINOGENESIS (2000)
Share Paper
